Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Summary of findings: risperidone showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with placebo (low certainty).
The review found no eligible studies for this question.
Summary of findings: haloperidol showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with placebo (low certainty).
Summary of findings: risperidone showed no clear difference in adverse events including extrapyramidal effectsd compared with placebo (low certainty).
It is very uncertain whether summary of findings: lorazepam plus haloperidol changes symptoms of delirium within 24 hoursa compared with placebo plus haloperidol (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings: lorazepam plus haloperidol changes agitation within 24 hoursc compared with placebo plus haloperidol (very low certainty).
It is very uncertain whether summary of findings: lorazepam plus haloperidol changes adverse events including extrapyramidal effectsd compared with placebo plus haloperidol (very low certainty).
The review found no eligible studies for this question.
Summary of findings: haloperidol showed no clear difference in adverse events including extrapyramidal effectse compared with placebo (moderate certainty).
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo (3 tablets/4 times a day (moderate certainty).
Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA)… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo + IVMA (moderate certainty).
The review found no eligible studies for this question.
Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with IMMA plus placebo (moderate certainty).
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
The review found no eligible studies for this question.
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in recurrence compared with placebo (3 tablets/4 times a day (low certainty).
Oral miltefosine (50 mg for 28 days) probably leads to higher complete cure, at least 3 months after the end of treatment compared with placebo (same regimen) (moderate certainty).